ESC: Catheter Ablation Aids Symptomatic Atrial Fibrillation, End-Stage Heart Failure
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 30, 2023 -- For patients with atrial fibrillation and end-stage heart failure, the combination of catheter ablation and guideline-directed medical therapy is associated with a lower likelihood of a composite of all-cause mortality, implantation of a left ventricular assist device, or urgent heart transplantation compared with medical therapy alone, according to a study published online Aug. 27 in the New England Journal of Medicine to coincide with the European Society of Cardiology Congress 2023, held from Aug. 25 to 28 in Amsterdam.
Christian Sohns, M.D., from Universitätsklinik der Ruhr-Universität Bochum in Germany, and colleagues assigned patients with symptomatic atrial fibrillation and end-stage heart failure who were referred for heart transplantation evaluation to receive catheter ablation and guideline-directed medical therapy (97 patients) or medical therapy alone (97 patients).
The researchers reported that catheter ablation was performed in 84 percent of the ablation group and in 16 percent of the medical therapy group. After a median follow-up of 18.0 months, a composite of death from any cause, implantation of a left ventricular assist device, or urgent heart transplantation occurred in eight patients in the ablation group and in 29 patients in the medical therapy group (hazard ratio [HR], 0.24; P < 0.001). Death from any cause similarly favored the ablation group (six patients in the ablation group versus 19 patients in the medical therapy group; HR, 0.29). Three patients in the ablation group and one patient in the medical therapy group had a procedure-related complication. The trial was stopped for efficacy by the data and safety monitoring board at one year postrandomization.
“Differences in the occurrence of primary end-point events between the trial groups appeared to emerge early and be sustained during follow-up,” the authors write. “However, consideration for catheter ablation should not postpone listing for transplantation.”
Several authors disclosed ties to the pharmaceutical or medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Gains in Heart Failure Mortality Have Been Erased
FRIDAY, April 26, 2024 -- Declines in heart failure-related mortality from 1999 to 2012 were entirely reversed from 2012 to 2021, according to a research letter published online...
Three-Month Blanking Period After A-Fib Ablation Should Be Shortened, Researchers Say
MONDAY, April 22, 2024 -- The three-month blanking period (BP) after atrial fibrillation (AF) ablation, when recurrences are not thought to predict long-term outcome, is called...
2000-2010 to 2011-2022 Saw Increase in Lifetime Risk for A-Fib
FRIDAY, April 19, 2024 -- From 2000 to 2022, there was an increase in the lifetime risk for atrial fibrillation, according to a study published online April 17 in The...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.